Oakwood Medical Investors II

Portfolio Companies

AtheroGenics, Inc. (NasdaqNM: AGIX) is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma, and arthritis.

Atairgin Technologies, Inc. is an emerging healthcare technology company dedicated to improving the quality of care in women's health. The company's platform technology is based on bioactive lipids that enable multiple platform applications in cancer, pregnancy management and reproductive health.

EndiCOR Medical, Inc. (acquired by ev3, Inc.) is a leading company in the development of next-generation interventional devices specifically designed to treat cardiovascular disease. EndiCOR's principal product is the X-SIZER® Catheter System, an easy-to-use, low cost, fully disposable device that combines vacuum with a spinning helix cutter located within the tip of a catheter. The X-SIZER® is designed to easily remove blockages, such as blood clots and soft tissue obstructions, from blood vessels to restore flow.          


Grifols (MCE: GRF.MC) is a group of healthcare companies serving healthcare professionals and patients in over 70 countries around the world. Grifols researches, develops, manufactures and markets plasma derivatives, IV therapy, enteral nutrition, diagnostic systems and medical materials.

Inhibitex, Inc. (NasdaqNM: INHX) is a biopharmaceutical company that is pursuing the development and commercialization of products for the infectious disease market. Inhibitex specializes in the development of products to prevent and treat infectious diseases, and specifically antibiotic-resistant bacteria, by using proteins that inhibit the attachment of the organism to human tissue, the first step in the disease process.

MedaSorb Technologies is dedicated to developing new and innovative technologies to potentially improve the quality of life for chronic renal (kidney) failure patients worldwide. MedaSorb is developing a filter technology to remove harmful substances from the blood of dialysis patients with chronic kidney failure, also known as end stage renal disease.

Nobex Corporation is a development stage drug delivery company specializing in proprietary polymer-based systems for the delivery and stabilization of protein and peptide drugs. The most advanced products in development are an oral insulin for treating Type II diabetes; oral APAZA™ for treating inflammatory bowel disease; and an oral calcitonin for treating osteoporosis.

Novacept, Inc. (acquired by Cytyc Corporation) was founded to design, develop, manufacture and market innovative therapeutic devices that improve the quality of women's healthcare in a cost- effective manner. Novacept's initial product, the Novasure Endometrial Ablation System is used to treat women who suffer from excessive menstrual bleeding.

ZYCOS Inc. (acquired by MGI PHARMA, Inc.) is developing therapeutic medicines targeting cancer, viral infections, and autoimmune disease. ZYCOS' discovery technology enables the rapid discovery of disease-specific antigens. ZYCOS has also developed a novel DNA expression system, DNA microsphere drug delivery system, and drugs able to adjust the body's defense mechanisms to treat disease.